المؤلفون: Felip, E., Cho, B. C., Gutiérrez, V., Alip, A., Besse, B., Lu, S., Spira, A. I., Girard, N., Califano, R., Gadgeel, S. M., Yang, J. C.H., Yamamoto, S., Azuma, K., Kim, Y. J., Lee, K. H., Danchaivijitr, P., Ferreira, C. G., Cheng, Y., Sendur, M. A.N., Chang, G. C., Wang, C. C., Prabhash, K., Shinno, Y., Stroyakovskiy, D., Paz-Ares, L., Rodriguez-Cid, J. R., Martin, C., Campelo, M. R.G., Hayashi, H., Nguyen, D., Tomasini, P., Gottfried, M., Dooms, C., Passaro, A., Schuler, M., Gelatti, A. C.Z., Owen, S., Perdrizet, K., Ou, S. H.I., Curtin, J. C., Zhang, J., Gormley, M., Ennis, M., Sethi, S., Bauml, J. M., Sun, T., Daksh, M., Panchal, A., Fennema, E., Lee, S. H.

المساهمون: Institut Gustave Roussy (IGR), Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Marseille (APHM), Janssen Research and Development

المصدر: ISSN: 0923-7534.

مصطلحات موضوعية: lazertinib, NSCLC, TP53, amivantamab, biomarkers, ctDNA, [SDV]Life Sciences [q-bio]

Relation: info:eu-repo/semantics/altIdentifier/pmid/38942080; PUBMED: 38942080

الاتاحة: https://hal.science/hal-04724689
https://hal.science/hal-04724689v1/document
https://hal.science/hal-04724689v1/file/1-s2.0-S0923753424007026-main.pdf
https://doi.org/10.1016/j.annonc.2024.05.541

المؤلفون: Sanz-Garcia, Enrique, Zou, Jinfeng, Avery, Lisa, Spreafico, Anna, Waldron, John, Goldstein, David, Hansen, Aaron, Cho, B. C. John, de Almeida, John, Hope, Andrew, Hosni, Ali, Hahn, Ezra, Perez-Ordonez, Bayardo, Zhao, Zhen, Smith, Christopher, Zheng, Yangqiao, Singaravelan, Nitthusha, Bratman, Scott V., Siu, Lillian L.

المساهمون: Conquer Cancer Foundation, Conquer Cancer Foundation - Young investigator Award (Enrique Sanz Garcia) BMO Chair in Precision Oncology (Lillian Siu) In-kind support of Neogenomics for ctDNA analysis

المصدر: Cell Death & Differentiation ; volume 31, issue 4, page 460-468 ; ISSN 1350-9047 1476-5403

الاتاحة: http://dx.doi.org/10.1038/s41418-024-01272-y
https://www.nature.com/articles/s41418-024-01272-y.pdf
https://www.nature.com/articles/s41418-024-01272-y

المؤلفون: Wihlidal, Jacob, Esemezie, Alex O., Huang, Shao Hui, Watson, Erin, Gilbert, Ralph W., Waldron, John, Gullane, Patrick J., Hope, Andrew, Irish, Jonathan C., O'Sullivan, Brian, Chepeha, Douglas B., Kim, John J. H., Brown, Dale, Cho, B. C. John, Witterick, Ian J., Monteiro, Eric, Davies, Joel C., Ringash, Jolie, Goldstein, David P., Bratman, Scott

المصدر: Annals of Surgical Oncology: An Oncology Journal for Surgeons; Feb2025, Vol. 32 Issue 2, p1270-1279, 10p

المؤلفون: Trigo, J., Cho, B. C., Park, K., Girard, N., Viteri, S., Garrido, P., Krebs, M. G., Thayu, M., Knoblauch, R. E., Xie, J., Bauml, J. M., Schnepp, R. W., Londhe, A., Mahadevia, P., Leighl, N.

المساهمون: Trigo, J. Hosp Univ Virgen Victoria & Reg, IBIMA, Malaga, Spain, Cho, B. C. Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea, Park, K. Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea, Girard, N. Inst Curie, Thorax Inst, Paris, France, Viteri, S. UOMI Canc Ctr, Clin Mi Tres Torres, Barcelona, Spain, Garrido, P. Hosp Univ Ramon & Cajal, IRYCIS, Madrid, Spain, Krebs, M. G. Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Manchester, Lancs, England, Krebs, M. G. Christie NHS Fdn Trust, Manchester Acad, Hlth Sci Ctr, Manchester, Lancs, England, Thayu, M. Janssen R&D, Spring House, PA USA, Knoblauch, R. E. Janssen R&D, Spring House, PA USA, Xie, J. Janssen R&D, Spring House, PA USA, Bauml, J. M. Janssen R&D, Spring House, PA USA, Schnepp, R. W. Janssen R&D, Spring House, PA USA, Londhe, A. Janssen R&D, Spring House, PA USA, Mahadevia, P. Janssen R&D, Spring House, PA USA, Leighl, N. Princess Margaret Canc Ctr, Toronto, ON, Canada, Janssen RD

Relation: http://hdl.handle.net/10668/21888; http://www.annalsofoncology.org/article/S0923753422001454/pdf; 778453100021

الاتاحة: http://hdl.handle.net/10668/21888
https://doi.org/10.1016/j.annonc.2022.02.029
http://www.annalsofoncology.org/article/S0923753422001454/pdf

المؤلفون: Cho, B. C.¹ cbc1971@yuhs.ac, Lu, S.², Felip, E.³, Spira, A. I.⁴, Girard, N.^5,6, Lee, J.-S.⁷, Lee, S.-H.⁸, Ostapenko, Y.⁹, Danchaivijitr, P.¹⁰, Liu, B.¹¹, Alip, A.¹², Korbenfeld, E.¹³, Dias, J. Mourão¹⁴, Besse, B.¹⁵, Lee, K.-H.¹⁶, Xiong, H.¹⁷, How, S.-H.¹⁸, Cheng, Y.¹⁹, Chang, G.-C.²⁰, Yoshioka, H.²¹

المصدر: New England Journal of Medicine. 10/24/2024, Vol. 391 Issue 16, p1486-1498. 13p.

مصطلحات موضوعية: *EPIDERMAL growth factor receptors, *POISONS, *NON-small-cell lung carcinoma, *ADVERSE health care events, *OSIMERTINIB

المؤلفون: Barlesi, Fabrice, Isambert, Nicolas, Felip, E., Cho, B. C., Lee, D. H., Peguero, J., Jerusalem, G., Penel, Nicolas, Saada-Bouzid, E., Garrido, P., Helwig, C., Locke, G., Ojalvo, L. S., Gulley, J. L.

المساهمون: Institut Gustave Roussy (IGR), Centre Régional de Lutte contre le cancer Georges-François Leclerc Dijon (UNICANCER/CRLCC-CGFL), UNICANCER, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille)

المصدر: ISSN: 1083-7159.

مصطلحات موضوعية: Bintrafusp alfa, TGF-beta, PD-L1, Bifunctional, Non-small cell lung cancer (NSCLC), [SDV]Life Sciences [q-bio]

Relation: info:eu-repo/semantics/altIdentifier/pmid/36571770; hal-04560295; https://hal.univ-lille.fr/hal-04560295; https://hal.univ-lille.fr/hal-04560295/document; https://hal.univ-lille.fr/hal-04560295/file/oyac253.pdf; PUBMED: 36571770

الاتاحة: https://hal.univ-lille.fr/hal-04560295
https://hal.univ-lille.fr/hal-04560295/document
https://hal.univ-lille.fr/hal-04560295/file/oyac253.pdf
https://doi.org/10.1093/oncolo/oyac253

المؤلفون: Passaro, A., Wang, J., Wang, Y., Lee, S. -H., Melosky, B., Shih, J. -Y., Azuma, K., Juan-Vidal, O., Cobo, M., Felip, E., Girard, N., Cortot, A. B., Califano, R., Cappuzzo, F., Owen, S., Popat, S., Tan, J. -l., Salinas, J., Tomasini, P., Gentzler, R. D., William, W. N., Reckamp, K. L., Takahashi, T., Ganguly, S., Kowalski, D. M., Bearz, A., MacKean, M., Barala, P., Bourla, A. B., Girvin, A., Greger, J., Millington, D., Withelder, M., Xie, J., Sun, T., Shah, S., Diorio, B., Knoblauch, R. E., Bauml, J. M., Campelo, R. G., Cho, B. C., Investigators, MARIPOSA-2

مصطلحات موضوعية: R Medicine (General)

Relation: Passaro, A. and Wang, J. and Wang, Y. and Lee, S. -H. and Melosky, B. and Shih, J. -Y. and Wang, J. and Azuma, K. and Juan-Vidal, O. and Cobo, M. and Felip, E. and Girard, N. and Cortot, A. B. and Califano, R. and Cappuzzo, F. and Owen, S. and Popat, S. and Tan, J. -l. and Salinas, J. and Tomasini, P. and Gentzler, R. D. and William, W. N. and Reckamp, K. L. and Takahashi, T. and Ganguly, S. and Kowalski, D. M. and Bearz, A. and MacKean, M. and Barala, P. and Bourla, A. B. and Girvin, A. and Greger, J. and Millington, D. and Withelder, M. and Xie, J. and Sun, T. and Shah, S. and Diorio, B. and Knoblauch, R. E. and Bauml, J. M. and Campelo, R. G. and Cho, B. C. and Investigators, MARIPOSA-2 (2024) Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Annals of Oncology, 35 (1). ISSN 0923-7534, DOI https://doi.org/10.1016/j.annonc.2023.10.117 .

الاتاحة: http://eprints.um.edu.my/45788/
https://doi.org/10.1016/j.annonc.2023.10.117

المؤلفون: Schmid, Sabine, Zhan, Luna, Garcia, Miguel, Dietrich, Kristen, Khan, Khaleeq, Chowdhury, Maisha, Herman, Michael, Patel, Devalben, Zaeimi, Fatemeh, Leighl, Natasha B, Sacher, Adrian, Feld, Ronald, Shepherd, Frances A, Donahoe, Laura, de Perrot, Marc, Cho, B C John, Liu, Geoffrey, Bradbury, Penelope A

المصدر: Schmid, Sabine; Zhan, Luna; Garcia, Miguel; Dietrich, Kristen; Khan, Khaleeq; Chowdhury, Maisha; Herman, Michael; Patel, Devalben; Zaeimi, Fatemeh; Leighl, Natasha B; Sacher, Adrian; Feld, Ronald; Shepherd, Frances A; Donahoe, Laura; de Perrot, Marc; Cho, B C John; Liu, Geoffrey; Bradbury, Penelope A (2024). Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma. (In Press). Clinical lung cancer Elsevier 10.1016/j.cllc.2024.04.011

مصطلحات موضوعية: 610 Medicine & health

وصف الملف: application/pdf

Relation: https://boris.unibe.ch/197465/

الاتاحة: https://boris.unibe.ch/197465/1/1-s2.0-S1525730424000664-main.pdf
https://boris.unibe.ch/197465/

المؤلفون: Mansoor, Wasat, Joo, S., Norquist, J. M., Kato, K., Sun, J. M., Shah, M. A., Enzinger, P., Adenis, A., Doi, T., Kojima, T., Metges, J. P., Li, Z., Kim, S. B., Cho, B. C., Sunpaweravong, P., Alsina Maqueda, M., Goekkurt, E., Suryawanshi, S., Shah, S., Shen, L.

المساهمون: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Relation: https://dx.doi.org/10.1093/oncolo/oyae087; Mansoor W, Joo S, Norquist JM, Kato K, Sun JM, Shah MA, et al. Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer. Oncologist. 2024 May 30. PubMed PMID: 38815152. Epub 2024/05/30. eng.; http://hdl.handle.net/10541/627043; The Oncologist

الاتاحة: http://hdl.handle.net/10541/627043
https://doi.org/10.1093/oncolo/oyae087

المؤلفون: Prenen, H., Deva, S., Keam, B., Lindsay, Colin R, Lugowska, I., Yang, J. C., Longo, F., de Miguel, M., Ponz-Sarvise, M., Ahn, M. J., Gumus, M., Champiat, S., Italiano, A., Salas, S., Perets, R., Arslan, C., Cho, B. C., Evers, S., Boetsch, C., Marbach, D., Dejardin, D., Sleiman, N., Ardeshir, C., Richard, M., Charo, J., Kraxner, A., Keshelava, N., Teichgräber, V., Moreno, V.

المساهمون: The Christie NHS Foundation Trust, Manchester, United Kingdom.

Relation: https://dx.doi.org/10.1158/1078-0432.ccr-23-2677; Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, et al. Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 May 6. PubMed PMID: 38709220. Epub 2024/05/06. eng.; http://hdl.handle.net/10541/627058; Clinical Cancer Research

الاتاحة: http://hdl.handle.net/10541/627058
https://doi.org/10.1158/1078-0432.ccr-23-2677

المؤلفون: Vansteenkiste, J. F., Naidoo, J., Faivre-Finn, Corinne, Özgüroğlu, M., Villegas, A., Daniel, D., Murakami, S., Hui, R., Lee, K. H., Cho, B. C., Kubota, K., Broadhurst, H., Wadsworth, C., Newton, M., Thiyagarajah, P., Antonia, S. J.

المساهمون: Division of Cancer Sciences, and Clinical Oncology, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom.

Relation: https://dx.doi.org/10.1016/j.jtocrr.2024.100638; Vansteenkiste JF, Naidoo J, Faivre-Finn C, Özgüroğlu M, Villegas A, Daniel D, et al. Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC. JTO clinical and research reports. 2024 Mar;5(3):100638. PubMed PMID: 38455595. Pubmed Central PMCID: PMC10918565. Epub 2024/03/08. eng.; http://hdl.handle.net/10541/626982; JTO Clinical Research Reports

الاتاحة: http://hdl.handle.net/10541/626982
https://doi.org/10.1016/j.jtocrr.2024.100638

المؤلفون: Yan, Michael, Sigurdson, Samantha, Greifer, Noah, Kennedy, Thomas A. C., Toh, Tzen S., Lindsay, Patricia E., Weiss, Jessica, Hueniken, Katrina, Yeung, Christy, Sugumar, Vijithan, Sun, Alexander, Bezjak, Andrea, Cho, B. C. John, Raman, Srinivas, Hope, Andrew J., Giuliani, Meredith E., Stuart, Elizabeth A., Owen, Timothy, Ashworth, Allison, Robinson, Andrew, de Moraes, Fabio Ynoe, Liu, Geoffrey, Lok, Benjamin H.

وصف الملف: application/pdf

Relation: Cancers 13 (12): 2895 (2021); http://hdl.handle.net/1807/105960

الاتاحة: http://hdl.handle.net/1807/105960
https://doi.org/10.3390/cancers13122895

المؤلفون: Perets, R., Bar, J., Rasco, D. W., Ahn, M-J, Yoh, K., Kim, D-W, Nagrial, A., Satouchi, M., Lee, D. H., Spigel, D. R., Kotasek, D., Gutierrez, M., Niu, J., Siddiqi, S., Li, X., Cyrus, J., Chackerian, A., Chain, A., Altura, R. A., Cho, B. C.

المساهمون: Kim, D-W

مصطلحات موضوعية: non-small-cell lung cancer, quavonlimab, MK-1308, CTLA-4, pembrolizumab, immunotherapy

Relation: Annals of Oncology, Vol.32 No.3, pp.395-403; https://hdl.handle.net/10371/189659; 000629497100015; 2-s2.0-85098213999; 134458

الاتاحة: https://hdl.handle.net/10371/189659

المؤلفون: Leighl N. B., Karaseva N., Nakagawa K., Cho B. -C., Gray J. E., Hovey T., Walding A., Ryden A., Novello S.

المساهمون: Leighl N.B., Karaseva N., Nakagawa K., Cho B.-C., Gray J.E., Hovey T., Walding A., Ryden A., Novello S.

مصطلحات موضوعية: EORTC QLQ-C30, EORTC QLQ-LC13, Non-small-cell lung cancer, Osimertinib, Patient-reported outcomes

Relation: info:eu-repo/semantics/altIdentifier/pmid/31838405; info:eu-repo/semantics/altIdentifier/wos/WOS:000505199600007; volume:125; firstpage:49; lastpage:57; numberofpages:9; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/2318/1720822; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85076114162; http://www.journals.elsevier.com/european-journal-of-cancer/

الاتاحة: http://hdl.handle.net/2318/1720822
https://doi.org/10.1016/j.ejca.2019.11.006
http://www.journals.elsevier.com/european-journal-of-cancer/

المؤلفون: Paz-Ares, L. G., Felip, E., Ahn, M. J., Blackhall, Fiona H, Borghaei, H., Cho, B. C., Johnson, M. L., Ramalingam, S. S., Reck, M., Zhang, A., Ju, C. H., Minocha, M., Mukherjee, S., Suri, G., Jandial, D., Bebb, D. G.

المساهمون: Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain

Relation: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS8611; Paz-Ares LG, Felip E, Ahn MJ, Blackhall FH, Borghaei H, Cho BC, et al. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005482.; http://hdl.handle.net/10541/626662; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/626662
https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS8611

المؤلفون: Lin, J. J., Drilon, A. E., Cho, B. C., Felip, E., De Langen, A., Yang, N., Kim, S. W., Lu, S., Kao, S. C. H., Velcheti, V., Moro Sibilot, D. L., Solomon, B. J., Dziadziuszko, R., Krebs, Matthew G, Cheema, P. K., Dooms, C. A., Stopatschinskaja, S., Trone, D., Ades, F., Camidge, D. R.

المساهمون: Massachusetts General Hospital Cancer Center, Boston, MA

Relation: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.9017; Lin JJ, Drilon AE, Cho BC, Felip E, De Langen A, Yang N, et al. Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion- positive ( ROS1 +) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003685.; http://hdl.handle.net/10541/626656; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/626656
https://doi.org/10.1200/JCO.2023.41.16_suppl.9017

المؤلفون: Minchom, A. R., Krebs, Matthew G, Cho, B. C., Lee, S. H., Leighl, N. B., O'Neil, B., Sabari, J. K., Kudgus-Lokken, R., Alhadab, A., Haddish-Berhane, N., Zemlickis, D., Mitselos, A., Berkay, E., Bauml, J. M., Knoblauch, R. E., Hellemans, P., Johnson, M. L.

المساهمون: Drug Development Unit at Royal Marsden Hospital/Institute of Cancer Research, Sutton

Relation: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.9126; Minchom AR, Krebs MG, Cho BC, Lee SH, Leighl NB, O'Neil B, et al. Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 dose. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003793.; http://hdl.handle.net/10541/626657; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/626657
https://doi.org/10.1200/JCO.2023.41.16_suppl.9126

المؤلفون: Paz-Ares, L., Spira, A., Raben, D., Planchard, D., Cho, B. C., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Hui, R., Murakami, S., Spigel, D., Senan, S., Langer, C. J., Perez, B. A., Boothman, A. M., Broadhurst, H., Wadsworth, C., Dennis, P. A., Antonia, S. J., Faivre-Finn, C.

المصدر: Paz-Ares , L , Spira , A , Raben , D , Planchard , D , Cho , B C , Özgüroğlu , M , Daniel , D , Villegas , A , Vicente , D , Hui , R , Murakami , S , Spigel , D , Senan , S , Langer , C J , Perez , B A , Boothman , A M , Broadhurst , H , Wadsworth , C , Dennis , P A , Antonia , S J & Faivre-Finn , C 2020 , ' Outcomes with durvalumab by tumour PD-L1 expression ....

مصطلحات موضوعية: durvalumab, immunotherapy, non-small-cell lung cancer, PACIFIC, PD-L1 expression, stage III

الاتاحة: https://research.manchester.ac.uk/en/publications/a5aec273-8cc5-490b-a998-902a4c784ffc
https://doi.org/10.1016/j.annonc.2020.03.287
http://www.scopus.com/inward/record.url?scp=85084203905&partnerID=8YFLogxK

المؤلفون: de Perrot, Marc, Wu, Licun, Cabanero, Michael, Perentes, J. Yannis, McKee, Trevor D., Donahoe, Laura, Bradbury, Penelope, Kohno, Mikihiro, Chan, Mei-Lin, Murakami, Junichi, Keshavjee, Shaf, Tsao, Ming-Sound, Cho, B. C. John

المساهمون: University Health Network

المصدر: The Journal of Thoracic and Cardiovascular Surgery ; volume 159, issue 5, page 2082-2091.e1 ; ISSN 0022-5223

الاتاحة: http://dx.doi.org/10.1016/j.jtcvs.2019.10.122
https://api.elsevier.com/content/article/PII:S0022522319325140?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0022522319325140?httpAccept=text/plain

المؤلفون: Wu, Y. -l., Mok, T. S. K., Lopes, G., Cho, B. C., Kowalski, D. M., Kasahara, K., de Castro Jr, G., TURNA, ZEYNEP HANDE, Cristescu, R., Aurora-Garg, D., Loboda, A., Lunceford, J., Kobie, J., Ayers, M., Pietanza, M. C., Piperdi, B., Herbst, R. S.

المساهمون: Chinese University of Hong Kong ,, 4312432

مصطلحات موضوعية: Sağlık Bilimleri, Klinik Tıp, ONKOLOJİ, Klinik Tıp (MED), Tıp, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji

Relation: ANNALS OF ONCOLOGY; Mok T. S. K., Lopes G., Cho B. C., Kowalski D. M., Kasahara K., Wu Y. -., de Castro Jr G., TURNA Z. H., Cristescu R., Aurora-Garg D., et al., "Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC", ANNALS OF ONCOLOGY, cilt.34, sa.4, ss.377-388, 2023; vv_1032021; av_0331ddd4-b62d-4daf-b8d5-dfdcafbed3fc; http://hdl.handle.net/20.500.12627/189212; https://doi.org/10.1016/j.annonc.2023.01.011; 34; 377; 388

الاتاحة: https://hdl.handle.net/20.500.12627/189212
https://doi.org/10.1016/j.annonc.2023.01.011